Anzeige
Mehr »
Login
Dienstag, 07.05.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
+56,25% in 5 Tagen: Genialer Schachzug - diese Übernahme verändert alles
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
44 Leser
Artikel bewerten:
(0)

Heart IT and Johns Hopkins Medicine Announce the Award of NIH Grant to Include Images in the Nationwide Health Information Network (NHIN)

DURHAM, N.C., Nov. 30, 2011 /PRNewswire/ --Heart IT, the global leader that pioneered the first FDA approved zero footprint medical imaging workstation and Johns Hopkins Medicine, announced the award of an NIH grant to enable the inclusion of medical images in the Nationwide Health Information Network (NHIN). The Nationwide Health Information Network (NHIN) is a federal initiative of the National Office of the Coordinator for Health Information Technology.

NHIN is being developed to provide a secure, nationwide, interoperable health information infrastructure that will connect providers, consumers, and others involved in supporting healthcare. This critical part of the national health agenda will enable health information to follow the consumer, be available for clinical decision making, and support appropriate use of healthcare information beyond direct patient care to improve health.

An ideal use of NHIN is the inclusion of medical images. According to the Government Accountability Office, 75% of all imaging procedures are performed outside of hospitals where PACS systems are practically non-existent. The smaller healthcare providers are simply not able to afford a PACS solution. Cost is the top barrier to adopt health information technology. However, the NHIN requires a PACS to share medical images. This implies that the most medical images - 75% of them - will not be available. Therefore, it is clear that a cost effective imaging solution is paramount as it can provide PACS capabilities to those smaller providers that cannot afford it.

Heart IT has developed WebPAX®, a unique product that offers PACS capability via a "Software-as-a-Service" (SaaS) model through Web 2.0 technologies that allow any internet web browser to function as a medical imaging workstation without the need to install client software. This technology includes zoom/pan, movie controls distance measurements and regions of interest. Heart IT has proposed this technology as a SaaS PACS for smaller providers in order to enable them to share and access images via the NHIN. To this end, Heart IT received a $2.25 million NIH grant and is collaborating with Johns Hopkins Medicine and its member hospitals to develop a prototype of this technology and demonstrate its value and capabilities within NHIN.

About Heart IT:

Founded in 2000 and headquartered near North Carolina's Research Triangle Park, Heart IT is a global leader in the medical image field. Their flagship product, WebPAX® is the first FDA approved zero foot-print medical image workstation. It provides web-based medical image management technology and services to health care systems, large hospitals and private clinics as well as drug and device companies sponsoring multi-center clinical trials. Worldwide, WebPAX® systems currently provide secure web browser access to over one billion medical images. For more information visit www.heartit.com.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com

SOURCE Heart IT

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2011 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.